Related Experiment Videos
Treatment of multiple sclerosis with mitoxantrone
E Mauch1, H H Kornhuber, H Krapf
1Department of Neurology, Ulm University, Dietenbronn/Schwend, Federal Republic of Germany.
European Archives of Psychiatry and Clinical Neuroscience
|January 1, 1992
Summary
Low-dose mitoxantrone effectively halted multiple sclerosis (MS) progression in ten patients. Most patients showed clinical and imaging improvements, with minimal side effects, indicating potential for MS management.
Area of Science:
- Neuroscience
- Oncology
- Immunology
Background:
- Multiple sclerosis (MS) is a chronic autoimmune disease characterized by rapid deterioration.
- Current treatments for aggressive MS have limitations and significant side effects.
Purpose of the Study:
- To evaluate the efficacy and safety of a reduced dosage of mitoxantrone in patients with rapidly progressing multiple sclerosis.
Main Methods:
- Ten MS patients with rapid disease progression received mitoxantrone (12 mg/m2) every 3 months.
- Clinical neurological status, visual evoked potentials (VEP), and magnetic resonance imaging (MRI) with gadolinium (Gd) enhancement were assessed.
Main Results:
- Disease deterioration halted in all patients; four showed immediate neurological improvement.
- Eight of nine patients improved clinically after 1 year; VEP P100 latencies reduced.
- MRI revealed a significant decrease in Gd-enhancing lesions from 169 to 10 in 12 months.
- Minimal side effects (nausea, faintness) were reported in six patients.
Conclusions:
- Low-dose mitoxantrone is effective in halting and potentially reversing disease progression in aggressive MS.
- Mitoxantrone demonstrates significant anti-inflammatory effects, reducing lesion activity.
- This regimen offers a favorable safety profile for managing rapidly deteriorating MS.